ESC Premium Access

Clinical Trial Update 1

Event: ESC CONGRESS 2017

Speakers: 6 speakers from this session

Topic: Miscellaneous

Session type: Clinical Trial Update

Date: 28 August 2017

Time: 14:00 - 15:30


6 presentations in this session

Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >=160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT

Speaker: Professor T. Wang (Taipei, TW)


Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: the AFFIRM Study

Speaker: Doctor M. Proietti (Milan, IT)


Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Speaker: Doctor R. Giugliano (Boston, US)


The long-term efficacy and safety of short dual antiplatelet therapy

Speaker: Professor M. Nakamura (Tokyo, JP)


Mechanisms for the benefit of spironolactone in resistant hypertension in the PATHWAY-2 study

Speaker: Professor B. Williams (London, GB)


Aldosterone Lethal Effects Blocked in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up

Speaker: Professor F. Beygui (Caen, FR)


6 speakers from this session

Professor Tzung-Dau Wang

National Taiwan University Hospital, Taipei (Taiwan)

3 presentations

Doctor Marco Proietti

University of Milan - Department of Pharmacological Sciences and Bio, Milan (Italy)

4 presentations

Doctor Robert Patrick Giugliano

Brigham and Women's Hospital, Department of Medicine, Cardiovascular Division, TIMI Study Group, Boston (United States of America)

22 presentations

Professor Masato Nakamura

Toho University Ohashi Medical Center, Tokyo (Japan)

4 presentations

Professor Bryan Williams

University College London, London (United Kingdom of Great Britain & Northern Ireland)

88 presentations

Professor Farzin Beygui

University Hospital of Caen, Caen (France)

8 presentations